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Cyclin kinase inhibitors are increased during experimental membra-
nous nephropathy: Potential role in limiting glomerular epithelial cell
proliferation in vivo. The inadequate proliferative response of the visceral
glomerular epithelial cell (GEC) following injury in vivo may contribute to
the development of progressive glomerulosclerosis in many forms of
glomerular disease. Cell proliferation is ultimately controlled by cell-cycle
regulatory proteins, including cyclins that bind to cyclin dependent kinases(CDK), and the active complex formed is necessary for progression
through the cell-cycle. By inhibiting cyclin-CDK complexes, cyclin kinase
inhibitors arrest the cell-cycle and prevent proliferation. To determine the
mechanisms that may be responsible for the lack of GEC proliferation in
vivo, we examined GEC expression of specific cell-cycle proteins in normal
rats and in the passive Heymann nephritis (PHN) model of membranous
nephropathy, where the GEC are the target of complement-mediated
injury. Following antibody deposition and complement activation there
was a marked up-regulation in the cyclin kinase inhibitors p2l and p27 in
rats with PHN. By associating with cyclin A-CDK2 complexes, p21 and p27
limited the kinase activity of CDK2. Giving bFGF to rats with PHN was
associated with an increase in GEC mitosis and ploidy and a decrease in
expression of p21, but not CDK2 or p27. Furthermore, apoptosis was not
present in PHN, but was increased in rats given bFGF. In conclusion, this
study shows that the low proliferative capacity of the GEC in vivo in
response to immune injury may be due to an increase in the expression of
specific cycliri kinase inhibitors. The increase in mitosis in PHN rats given
bFGF may be due to a decrease in p2l. Thus, changes in cell cycle
regulatory proteins may regulate the response of GEC to injury and
underlie the development of progressive glomerulosclerosis in diseases of
the GEC.
The glomerular visceral epithelial cell (GEC) (also called
podocyte) is a complex cell that lines the outer surface of the
glomerular capillary wall, and plays a critical role in maintaining
the filtration barrier [1]. Injury to the GEC is central to the
development of proteinuria and progressive glomerulosclerosis in
many forms of renal disease, including glomerulonephritis, diabe-
tes mellitus, HIV and reduced nephron mass [2, 3].
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One mechanism by which GEC injury leads to glomeruloscle-
rosis may be the inability to proliferate following injury such that
glomerular capillary hypertrophy occurs without the correspond-
ing increase in GEC number necessary to maintain an epithelial
cell layer over all areas of the glomerular basement membrane [4].
This lack of proliferation contrasts with glomerular mesangial and
endothelial cells, which vigorously proliferate following injury in
vivo [5, 6]. During nephrogenesis, GEC do proliferate during the
development of the S-shaped bodies, but stop proliferating during
the capillary loop stage [1, 7]. Many support the notion that while
the "mature" GEC phenotype has the ability to undergo limited
DNA synthesis, it is unable to undergo cell division (cytokinesis).
In human [8, 9] and experimental studies [10, 11] injury to the
GEC has been associated with mitosis and even ploidy, but the
number of GEC does not increase. Kriz et al and Floege et al have
shown that augmenting GEC injury by infusing bFGF in rats with
the passive Heymann nephritis (PHN) model of experimental
membranous nephropathy leads to an increase in the number of
GEC with mitotic figures and ploidy, but the glomerular cell
number did not increase [11, 12]. These observations suggest that,
unlike the mesangial cell and glomerular endothelial cell, the
GEC has a very limited proliferative capacity in vivo.
Cell proliferation is ultimately controlled at the level of the
cell-cycle by a number of intricately linked nuclear proteins, called
cell-cycle regulatory proteins [13]. These include GuS phase
cyclins and cyclin-dependent kinases (CDK) that are necessary for
GuS transition and DNA synthesis, as well as cyclin kinase
inhibitors (CM) that arrest the cell cycle and thereby limit
proliferation [14, 15]. The G2/M phase cyclins are required for
mitosis [16]. In a previous study on GuS cell cycle regulatory
proteins in glomerular disease, we documented that antibody-
complement induced mesangial cell proliferation in the experi-
mental mesangial proliferative glomerulonephritis (ATS model)
is associated with an increase in specific cyclins and CDKs in
mesangial cells, accompanied by a decrease in the cyclin kinase
inhibitor p27' (p27) [17]. In the ATS model the two cyclin
kinase inhibitors, p27 and 21cIP1rWAF1IcAP1/sDI1 (p21), appeared
to have major roles in maintaining the mesangial cell in quies-
cence and in terminating cell proliferation, respectively [17].
Although defects involving either GuS phase cyclins or G2/M
phase cyclins might account for the apparant inability of GEC
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proliferation in vivo, we have focused here on the GuS phase
only. We reasoned that the failure of the GEC to proliferate in
response to a similar form of immune injury might reflect a
different pattern of changes in cell cycle regulatory proteins and to
possibly involve the persistent expression of various cyclin kinase
inhibitors. To test this hypothesis we determined the glomerular
expression of several GuS cyclins and CDKs, as well as CKI in
normal rats and in the passive Heymann nephritis (PHN) model
of membranous nephropathy in rats induced by antibody to GEC
membrane antigens and complement. Our results confirm that the
GEC response to immune injury differs from that of the mesangial
cell and is characterized by a marked up-regulation of the CM,
p21 and p27, which likely limit GEC proliferation. When GEC
proliferation is induced with exogenous bFGF, there is a selective
and significant reduction in p21 expression. These results indicate
that the relative lack of proliferation of GEC in response to injury
is determined by a differential expression of cell cycle regulatory
proteins.
METHODS
Experimental design
Experimental membranous nephropathy (passive Heymann ne-
phritis, PHN) was induced in male Sprague-Dawley rats (Simon-
sen, Gilroy, CA, USA) weighing 180 to 200 g by intraperitoneal
injection (5 ml/kg body wt) of sheep antibody to Fx1A prepared as
previously described [18]. Rats with PHN were sacrificed at 3, 5
and 10 days (N = 6 at each time point) for renal biopsies and
glomerular isolation [19]. To determine the effects of bFGF on
the expression of cell cycle proteins and apoptosis in rats with
PHN, an additional twelve rats with PHN were injected intrave-
nously with either human recombinant bFGF (5 jig) on days 3 and
4; (N = 6) or with vehicle (N = 6) as previously described [12],
and sacrificed on day 5 for renal biopsies and glomerular isolation.
Urine protein excretion was determined in control and PHN
animals using the sulphosalicylic acid method [20].
Indirect immunoperoxidase immunostaining
Renal biopsies were fixed in either methyl Carnoy's solution or
formalin, and embedded in paraffin. Indirect immunoperoxidase
double-staining on 4 jim sections was performed as previously
described [17]. The following first primary rabbit polyclonal
antibodies were incubated overnight at 4°C: cyclin Dl (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), cyclin D2 (Santa Cruz
Biotechnology), cyclin E (provided by J.M. Roberts), cyclin A
(provided by J.M. Roberts), cyclin dependent kinase 2 (Santa
Cruz Biotechnology), cyclin dependent kinase 4 (Santa Cruz
Biotechnology), p1 51NK4 (p15) (Santa Cruz Biotechnology), p21
(Santa Cruz Biotechnology) and p27 (provided by J.M. Roberts).
Controls for this step included omitting the primary antibody,
substituting the primary antibody with pre-immune rabbit serum
and peptide absorption studies (peptides obtained from the same
source as the primary antibody) A biotinylated goat anti-rabbit
secondary antibody (Vector Laboratories Inc., Burlingame, CA,
USA) was then added, followed by a horseradish peroxidae
conjugated avidin D (Vector Laboratories Inc.). Black nuclear
staining was detected using diaminobenzidine (Sigma Chemical
Co., St. Louis, MO, USA) with nickel as a chromagen.
To determine which cell-type was expressing p21 and p2'7,
double-immunostaining was then performed using a second pri-
mary antibody specific for the GEC. We used the monoclonal
antibody to SPARC (Haemotologic Technologies Inc., Essex Jct.,
VT, USA), which has been previously shown to be selectively
increased in GEC in PHN [21], and the antibody was incubated
overnight at 4°C. A secondary peroxidase-conjugated anti-mouse
IgG antibody (Zymed Laboratories) was applied for 60 minutes at
room temperature. The brown cytoplasmic stain was determined
using diaminobenzidine without nickel. The controls for the
second step of the double-immunostaining included omitting the
primary antibody or replacing it with an irrelevant antibody of the
same Ig class.
The glomerular expression for each cell-cycle protein was
semiquantitated in a blinded fashion by counting the number of
glomerular nuclei expressing each antigen at each time point.
Each rat was individually assessed. Fifty glomerular cross-sections
from each biopsy were evaluated, and a mean value per time point
was calcuated, and expressed as positive cells per 50 glomerular
cross sections SD.
Immunofluorescence staining for glomerular rat IgG, C3, C5b-9
Detection of rat IgG, C3, C5b-9 and sheep IgG in glomeruli was
carried out on 4 jim sections of ether/alcohol fixed frozen kidney
tissue using direct (rat IgG, C3) or indirect (C5b-9) immunoflu-
orescence staining as described elsewhere [22]. Sections were
studied with fluorescein-conjugated IgG fractions of monospecific
antisera to rat IgG, and rat C3 (Cappel Laboratories, Cochrane-
ville, PA, USA) and biotinylated 2A1, a murine monoclonal
antibody to a neoantigen of C5b-9 [23], followed by fluorescein-
conjugated streptavidin (Amersham, Arlington Heights, IL,
USA).
Western blot analysis
Glomeruli were isolated from the renal cortex by differential
sieving as previously described [19]. To extract glomerular protein
the glomeruli were resuspended in a buffer containing 1% triton,
10% glycerol, 20 m HEPES, 100 m NaCI with 10 jig/ml
leupeptin, 10 jig/mI antipain, 10 jig/ml pepstatin (Sigma Bio-
sciences, St. Louis, MO, USA), 0.1 m sodium orthovanadate and
50 mi sodium fluoride (Sigma Biosciences) [17]. Glomeruli were
sonicated for 20 seconds and placed on ice for 10 minutes
followed by centrifugation at 14,000 rpm for five minutes. The
protein concentration in the supernatant was measured by BCA
protein assay (Pierce, Rockford, IL, USA). Glomerular protein
extracts (20 jig) were separated under reduced conditions on a
15% SDS-PAGE gel. Protein was transferred to PVDF mem-
branes (Millipore, Bedford, MA, USA) by electroblotting, and
following Western blot analysis, filters were stained with Coomas-
sic brilliant blue and destained, to ensure complete protein
transfer. Membranes were blocked in 5% nonfat dried milk for 20
minutes before incubation with antibodies to cyclin A, CDK2,
p15, p21 and p27 (sources as listed earlier). An alkaline phos-
phatase-conjugated secondary antibody was used (Promega, Mad-
ison, WI, USA) with BCIP/NBT (Sigma Biosciences) as substrate.
Controls included omitting the primary antibody, and peptide
absorption for each primary antibody.
Histone kinase Hi assay and co-immunoprecipitation studies
The activity of cyclin dependent kinase 2 was determined by the
Histone Hi assay as previously described [17]. Briefly, glomerular
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protein extracts (1000 p.g) were immunoprecipitated with anti-
bodies to cyclin A, or CDK2 for 30 minutes at 4°C. Fifty
microliters of Protein A sepharose beads (Repligen, Cambridge,
MA, USA) were added to each immunoprecipitation and incu-
bated for 30 minutes at 4°C. Negative controls included substitut-
ing pre-immune rabbit serum for the antibodies. Recombinant
cyclin A-CDK2 (provided by J.M. Roberts) was used as a positive
control. For the kinase assay, Histone Hi (Boehringer Mannheim,
Indianapolis, IN, USA), ATP (Pharmacia Biotech, Piscataway,
NJ, USA) and [32P] dCTP (Dupont, Boston, MA, USA) were
added for a 60 minute incubation at 37°C. Reduced sample
buffer was then added, and the mix was separated on a 15%
SDS-PAGE gel. The gel was exposed to autoradiographic film
(Amersham), and densitometry analysis [10j was used to
quantitate the kinase activity. Histone HI assays were per-
formed in duplicate.
To determine if the cyclin kinase inhibitors p21 or p27 were
bound to cyclin A-CDK2 complexes in control and PHN rats, a
co-immunoprecipitation was performed. Giomerular lysates (500j.g) from control and PHN rats was first immunoprecipitated
with an antibody to cyclin A, then incubated with protein A
beads, and separated by gel electrophoresis. A Western blot
analysis was performed with antibodies to p21 or p27 as
described earlier.
Apoptosis was measured by the TUNEL assay
To measure apoptosis in control and diseased rats, we used the
TUNEL assay as previously described [24]. Briefly, formalin fixed
slides were deparaffined and rehydrated in ethanol, followed by an
antigen retrieval step involving boiling the tissue in citric acid (pH
6.0). Samples were incubated in Proteinase K (6.2 p.g/ml; Boehr-
inger Manneheim), followed by TdT (300 enzyme U/mI; Pharma-
cia Biotech) and Bio-14-dATP (0.94 nm; Gibco BRL, Grand
island, NY, USA). Biotynilated ATP was detected using the ABC
staining method (Vector Laboratories; following the manufactur-
er's protocol). As a positive control, slides were treated with
DNAse (20 Kunitz U/mi; Sigma Biosciences).
Statistical analysis
All scores for immunohistochemical staining were expressed as
mean SD unless stated otherwise. Statistical significance (de-
fined as P < 0.05) was evaluated by use of the Student's t-test or
one-way analysis of variance with modified t-test performed with
the Bonferroni correction.
RESULTS
Cyclin A is increased in PHN
Figure 1 shows a Western blot for cyclin A performed on
protein lysates from isolated glomeruli from normal rats and PHN
rats. At day 3 following GEC injury in PHN there was a slight
increase in cyclin A protein levels, which were also increased at
day 5. By day 10, protein levels for cyclin A had returned to
baseline. In addition to carefully ensuring that 20 p.g of protein
was loaded in each lane for Western blot analysis, we stained all
filters in the current study with Coomassie brilliant blue to ensure
that the protein loading was equal (results not shown). Immuno-
staining of renal tissue with an antibody to cyclin A confirmed the
increase in cyclin A protein, and showed that the pattern of
staining was in a typical GEC distribution (results not shown).
Fig. 1. Western blot analysis for cyclin A. Twenty micrograms of glomer-
ular protein was loaded in each lane, and seperated on a 15% a
SDS-PAGE, and immunoblotted with an antibody to cyclin A. No protein
was detected in control glomeruli (C). There was an increase in cyclin A
protein at day 3 (D3) and day 5 (D5) of PHN, which had normalized by
day 10 (D10). Molecular weight markers in kDa are shown in the left
margin.
Absorbing the antibody to cyclin A with a specific peptide resulted
in the absence of nuclear immunostaining, and the absence of
cyclin A antigen by Western blot analysis, thereby confirming
antibody specificity.
In control rats and in PHN rats, expression for cyclin Dl, cyclin
D2 or cyclin E was not detected by immunostaining or Western
blot analysis at any of the time points in the current study (results
not shown). The inability to detect the expression of these
antigens was not due to the antibodies used in the current study,
as we have shown that they recognize antigens in rat glomerular
cells in culture, and we have documented that they detect rat
nuclear antigens in vivo [17].
Cyclin dependent kinase 2 (CDK2) is increased in PHN
The protein levels for CDK2 measured by Western blot analysis
performed on glomerular lysates were increased at day 3 and 5 of
PHN (results not shown). Figure 2 shows immunostaining for
CDK2. GEC injury in PHN was associated with a mild increase in
cells staining positive for CDK2 at day 3 and day 5 of disease
compared to control (3.0 0.3 vs. 0.5 0.1 positive cells/
glomerulus, P < 0.05 vs. control), and the glomerular cells that
stained positive for CDK2 were predominantly in a GEC distri-
bution (Fig. 2). Staining for CDK2 had reached baseline levels by
day 10 of disease.
To determine if the functional activity for CDK2 was also
increased in disease, we performed a histone Hi kinase assay on
glomerular lysates. Recombinant cyclin A-CDK2 complexes (pro-
vided by J.M. Roberts) were used as a positive control. Figure 3
shows that compared to control, CDK2 kinase activity (measured
by densitometry) had increased 1.6-fold by day 3, and 1.3-fold by
dayS of PHN. The specificity of the antibody used to detect CDK2
in the current study was confirmed by peptide absorption, and by
Western blot analysis (results not shown).
There was no detectable increase in immunostaining for CDK4
in PHN at the time points studied (results not shown).
p21 is up-regulated in PHN, and binds to cyclin A-CDK2
Figure 4 shows a Western blot analysis performed on glomer-
ular protein lysates with an antibody specific for the p21 antigen,
and confirms the increase in p21 in a rat with PHN. p21 expression
was increased at days 5 and 10 of PHN. Figure 5 shows immuno-
staining for p21 in control rats and rats with PHN. As we have
previously described [17], p21 staining was minimally detected in
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Fig. 2. Indirect immunoperoxidase immunostaining for cyclin dependent kinase 2 (CDK2). In the normal rat glomerulus, no staining was observed for
CDK2 (A). (B) A representative glomerulus at day 3 of PHN that shows an increase for nuclear staining positive for CDK2. In this glomenilus, three
cells stained positive for CDK2, and these were in a typical GEC distribution.
Fig. 5. Indirect immunoperoxidase double-
immunostaining for p21 (represented by the
black nuclear stain), and SPARC, a marker of
the glomerular epithelial cell (represented by
the brown cytoplasmie stain). (A). In the
normal rat glomerulus, no staining was
observed for p21. (B). A representative
glomerulus at day 5 of PHN that shows a
marked increase in cells displaying nuclear
staining for p21 (examples are indicated by the
broad arrows), colocalizing with SPARC
staining cells (examples are indicated by the
thin arrows). Magnification X63.
Fig. 9. Indirect immunoperoxidase double-
immunostaining for p27 (represented by the
black nuclear stain), and SPARC, a marker of
the activated glonserular epithelial cell
(represented by the brown cytoplasmic stain).
(A). In the normal rat glomerulus, nuclear
staining was observed for p27 in all three
resident glomerular cell types. (B) A
representative glomerulus at day 5 of PHN that
shows an increase in cells displaying nuclear
staining for p27 (examples are indicated by the
broad arrows), colocalizing with SPARC
staining cells (examples are indicated by the
thin arrows). Magnification X63.
the normal rat glomerulus. However, following immune-medi-
ated injury to the GEC in PHN, there was a six- to sevenfold
increase in the number of cells staining positive for both p21
and SPARC (a marker of GEC) at all time points in the current
study (P < 0.05 vs. control; Fig. 6). p21 staining was seen only in the
GEC (SPARC positive cells). Nuclear immunostaining was absent
when the antibody to p21 was peptide absorbed, confirming antibody
specificity.
To determine if p21 was bound to cyclin A-CDK2, we per- . . .
Fig. 13. Immunostaining for TUNEL. (A) TUNEL staining is absent atformed a co-Immunoprecipitation. As shown in Figure 7, the day 5 of PHN. (B) Cells that stain positively for TUNEL (represented by
binding of p21 to cyclin A-CDK2 was the reciprocal of the kinase the arrow).
U S t 4
 
0 
e
 
r 
t 
I- 
a
 
a
 
S 
e
 
-
 
S.
 
•
 
•
 
S 
.
 
a
 
s'
s 
A 9 .
S.
• .
'—I.•It • •.4 •
.*
• a -
B0.
-
1.41/ -'
'Lb
408 Shankland et al: Cell cycle and glomerular epithelial cell
45 —
29
18
C D5 D10
..uI— p21
Fig. 3. Cyclin dependent kinase 2 (CDK2) kinase activity. CDK2 activity
was measured by a histone Hi kinase assay. Each lane represents 1000 .rg
of glomerular protein extracted from control rats (C) or rats with PHN,
that was immunoprecipitated with an antibody to cyclin A. There was a
1.6-fold increase in CDK2 kinase activity as represented by an increase in
protein with a molecular weight of 33 kDa consistent with histone Hi at
day 3 (D3) of PHN, and a 1.3-fold increase at day 5 (D5) of PHN
compared to control. Recombinant cyclin A-CDK2 complexes were used
as positive controls (lane 4). Molecular weight markers in kDa are shown
in the left margin.
activity (shown in Fig. 3), with a slight increase in binding at day
3, and a maximal increase at day 5.
p27 expression increases in disease, and limits cyclin A-CDK2
kinase activity
Figure 8 shows a Western blot analysis performed on glomer-
ular protein lysates with an antibody to p27, and demonstrates
that p27 protein levels are increased in PHN. Figure 9 shows
immunostaining for the cyclin kinase inhibitor p27. Although all
three glomerular cell types stain for p27 in the normal glomerulus,
not all normal GEC stain positively for p27. The onset of
complement-mediated injuly to the GEC in PHN was associated
with an increase in p27 staining, and double-staining with SPARC,
showed that the number of GEC expressing p27 had increased
two- to threefold in PHN (Fig. 10). Nuclear immunostaining
was absent when the antibody to p27 was peptide absorbed,
confirming antibody specificity. Similar to the staining de-
scribed earlier, there was an increase in p27 protein levels in
PHN, and the increase coincided with the onset of proteinuria
in this model.
As shown in Figure ii, although p27 associated with cyclin
A-CDK2 complexes in the normal glomerulus, there was in-
creased binding at days 3 and 5 of disease. The increased binding
of p27 with cyclin A-CDK2 complexes at day 5 was the reciprical
of the kinase activity.
In the normal rat glomerulus, immunostaining showed that
p15"4 (p15) is abundantly expresssed in all three resident cell
types. However, there was no change in the expression of p15 in
PHN by immunostaining or Western blot analysis (results not
shown).
bFGF decreases the expression of p21 in PHN
As previously described, giving bFGF to PHN rats augments
GEC injury, increasing the number of GEC mitotic figures and
ploidy [121. To determine if this was associated with an alteration
Fig. 4. Western blot analysis for p2!. Twenty micrograms of glomerular
protein was loaded in each lane, and separated on 15% SDS-PAGE, and
immunoblotted with an antibody specific to p21. There was an increase in
p21 protein (represented by a protein with a 21 kDa size) at day 5 (D5)
and day 10 (Di0) of PHN compared to control (C). Molecular weight
markers in kDa are shown in the left margin.
in cell-cycle protein expression, PHN rats received bFGF or
vehicle, and the results are shown in Figure 12. There was a
marked decrease in the protein levels for p21 in the bFGF-treated
group compared to the vehicle-treated group. Staining for p21 was
also decreased in bFGF treated rats compared to vehicle (results
not shown). In contrast, bFGF did not alter the protein levels for
CDK2, p15 or p27 by Western blot analysis (Fig. 12), or by
immunostaining (results not shown).
Apoptosis
We used a TUNEL assay to measure apoptosis in normal rats,
PHN rats, and PHN rats treated with bFGF or vehicle. There was
no increase in glomerular apoptosis at days 3, 5 and 10 of PHN
compared to control. Tissue sections from different experimental
rat models were used as positive controls. Augmenting GEC
injury with bFGF caused an eightfold increase in the number of
glomerular cells staining positive for TUNEL (P < 0.05 vs. vehicle
treated; Fig. 14). TUNEL positive cells were typically in a GEC
distribution (Fig. 13).
DISCUSSION
In the current study we show that, in the PHN model of GEC
injury, the low proliferative response of the visceral glomerular
epithelial cell (GEC) or podocyte to immune injury in vivo is
associated with an up-regulation in specific cyclin kinase inhibi-
tors. The observation that p21 expression was decreased in
association with increased GEC DNA synthesis by giving bFGF to
PHN rats suggests a functional role for this cyclin kinase inhibitor
in limiting GEC proliferation in disease. We also show that
augmenting complement-mediated GEC injury in PHN rats with
bFGF was associated with an increase in GEC apoptosis.
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Fig. 6. Quantitation of p21+/SPARC+ staining. Shown are the number
of cells that double-stained for p21 and SPARC (a marker of the
glomerular epithelial cell) in each glomerular cross-section from control
rats (C) and at different days in the PHN model (days labeled as d). Each
time point represents the mean SD of six animals. There was an increase
in p21 +/SPARC+ cells at days 3, 5 and 10 of PHN (*P < 0.001 vs. C).
Cyclin A and CDK2 expression and activity are increased in PHN
Studies have suggested that the inability of the mature visceral
GEC to proliferate in vivo following injury is a critical determi-
nant in the development of progressive glomerulosclerosis in both
immune and non-immune mediated injury [4]. This contrasts to
the parietal glomerular epithelial cell, mesangial cell and glomer-
ular endothelial cell, which proliferate vigorously in response to
many forms of glomerular injury [25]. Although many regard the
GEC as a "post-mitotic" cell, the mature GEC has the capacity,
albeit limited, to engage the cell cycle. We and others have
previously documented that GEC in vivo can synthesize DNA and
undergo mitosis [9, 10, 12]. Because DNA synthesis in non-renal
and renal cells in vitro is due to an increase in certain positive cell
cycle regulatory proteins, our first aim was to examine these
proteins following GEC injury in vivo. We studied the PHN model
of experimental membranous nephropathy where proteinuria
follows injury to the GEC induced by antibody and sublytic C5b-9
[26, 27].
During each phase of the cell-cycle there is an increase in
expression for specific cyclins, which bind to their catalytic part-
ners, the cyclin-dependent kinases (CDK) to form active cyclin-
CDK complexes [14, 28]. The D-cyclins bind CDK4 in GI [291,
whereas cyclin E-CDK2 complex at the GuS transition [30].
Cyclin A is complexed with CDK2 during the S phase [31]. Thus,
the first aim of the current study was to determine the expression
and activity of cell cycle proteins that are required for DNA
synthesis. Complement-mediated GEC injury in PHN is associ-
ated with a low grade increase in the expression of cyclin A and its
partner, CDK2. Furthermore, the functional activity of cyclin
A-CDK2 was slightly increased, and this corresponded to the low
grade GEC DNA synthesis that we have previously reported [10].
Fig. 7. Co-immunoprecipitation for p2! and cyclin A-CDK2. Five hun-
dred micrograms of glomerular protein from control (C) rats and PHN
rats was first immunoprecipitated with an antibody to cyclin A, separated
on a 15% SDS-PAGE, and then immunoblotted with an antibody to p21.
Binding of p21 to cyclin A-CDK2 complexes was progressively increased
at day 3 (lane 2) and day 5 (lane 3) of PHN compared to control (lane 1).
The increase coincided with a decrease in CDK2 kinase activity (shown in
Fig. 3). Molecular weight markers in kDa are shown in the left margin.
Thus, following injury, quiescent GEC can enter and progress
through the cell cycle by increasing the expression and activity of
specific positive cell cycle regulatory proteins. Like certain other
"post-mitotic" cells such as lymphocytes and fibroblasts, the GEC
can therefore re-engage the cell cycle following certain stimuli
such as injury. This contrasts with cells such as neurons and
skeletal muscle, which cannot undergo new DNA synthsis once
they are fully differentiated. Although we did not show an increase
in cyclins Dl, D2 or E, and CDK4 in the current study, this may
have been due to the inability to detect these proteins with the
methods used or changes in expression may have occurred at time
points not examined in the current study.
p21 and p27 are up-regulated following GEC injury, and bind to
CDK2
Cyclin-kinase inhibitors (CM) negatively regulate the cell cycle
by inhibiting cyclin-CDK complexes [32]. One family of CM is
known as the CIP/MP family, and include 2iCPl WAFI, SD!1
(abbreviated as p21 in this manuscript) [33—35] and p27'°1,
(abbreviated as p27 in this manuscript) [36—38]. The N-termini of
these CKI share homology, and bind to and inhibit a variety of
cyclin-CDK complexes [37],
Because the overexpression of p21 [39] or p27 [37] prevents
proliferation of certain cells in vitro by binding to cyclin-CDK
complexes, and reducing the expression of p27 with antisense
oligodeoxynucleotides results in entry into the cell cycle [40, 41],
the second aim of the current study was to examine if the low
proliferative capacity of the GEC in vivo was due to an increase in
the expression of cyclin kinase inhibitors, p15, p21 and p27. We
show that GEC injury in the PHN model was associated with an
up-regulation of both p21 and p27. Double-immunostaining with
cell-specific markers localized the increase to the GEC. Because
an increase in the expression of p21 and p27 per se does not imply
binding, we performed co-immunoprecipitation studies to ask if
these inhibitors were indeed responsible for limiting the func-
tional (kinase) activity of CDK2. Our results show that p21
binding to cyclin A-CDK2 was increased in PHN, and the increase
was reciprocal to the activity of CDK2. In rats with PHN, the
binding of p27 to cyclin A-CDK2 was also increased. Thus, not
only was the expression of p21 and p27 increased in PHN, but
there was an increase in binding of p21 and p27 to cyclin A-CDK2
complexes. In contrast to the increase in p21 and p27, there was
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Fig. 10. Quantitation of p27+/SPARC+ staining. The number of cells
that double-stained for p77 and SPARC (a marker of the glomerular
epithelial cell) in each glomerular cross-section from control rats (C) and
at different days in the PUN model (days labeled as d) are shown. Each
time point represents the mean soof six animals. There was an increase
in p27+/SPARC+ cells at days 3, 5 and 10 of PF-IN (*P < 0-001 vs. C).
no increase in levels of the cyclin-kinase inhibitor p15 in PUN.
These results suggest that p21 and p27 may be up-regulated by
antibody-complement attack and be responsible for the limited
kinase activity in PUN (compared to the ATS model of experi-
mental mesangial proliferative glomerulonephritis [17]), and
therefore the limited proliferative capacity of the GEC following
injury.
The mechanisms responsible for the increase in p21 and p77
expression in PUN were not studied in this experiment. TGF-13
increases the expression of p21 and p771 in certain cells in vitro [38,
42]. We have recently shown that specific TGF-f3 isoforms and
receptors are increased in GEC in PUN [43]. Furthermore,
Morrissey et al have shown that TOE-p increases the expression
of p21 in vivo [44]. Taken together, the increase in p21 and p77
expression in PUN may be due to the up-regulation of TGF-13,
and further studies are needed to address this hypothesis.
Fig. 12. Western blot analysis for CDK2, p15, p21 and p27at day 5 from
PUN rats given bFGF or vehicle. Twenty micrograms of glomerular
protein were loaded in each lane, and separated on 15% SDS-PAGE.
Lane 1 represents PUN animals that received vehicle, and lane 2
represents PUN animals that reveived bFGF. There was no change in the
protein levels for CDK2, p15 or p77 in PUN rats treated with bFGF
compared to vehicle treated animals. There was a striking decrease in the
protein levels for p21 in PHN animals receiving bFGF compared to
vehicle treated animals.
Complement-mediated glomerular injury is one of the leading
mechansims of renal disease. In experimental models induced by
antibody to glomerular cell membranes such as the PUN model
induced by anti-GEC antibody [18], the ATS model induced by
antibody to mesangial cells [45], and the model of thrombotic
Fig. 11. Co-immunoprecipitation for p27 and cyclin A.CDK2. Five hun-
dred micrograms of glomerular protein from control (C) rats and PUN
rats were first immunoprecipitated with an antibody to cyelin A, separated
on 15% SDS-PAGE, and then immunoblotted with an antibody to p77.
Binding of p77 to cyclin A-CDK2 complexes was progressively increased
at day 3 (lane 2) and day 5 (lane 3) of PUN compared to control (lane 1).
The increase in p27 binding coincided with a decrease in CDK2 kinase
activity (shown in Fig. 3). Molecular weight markers in kDa are shown in
the left margin.
Fig. 8. Western blot analysis for p27. Twenty micrograms of glomerular
protein were loaded in each lane, and separated on 15% SDS-PAGE, and
immunoblotted with an antibody specific to p77. There was an increase in
p27 protein (represented by a protein with a 27 kDa size) at day 3 (D3),
day 5 (D5) and day 10 (D10) of PHN compared to control (C). Molecular
weight markers in kDa are shown in the left margin.
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Fig. 14. Quantitation of TUNEL staining. There is an eightfold increase(*P < 0.05) in the number of glomerular cells that stain for TUNEL in
PHN rats given bFGF (bfgf) compared to control (C), rats with PHN at
day 3 (d3), day 5 (d5) and day 10 (dlO), and PHN rats given vehicle (veh).
microangiopathy induced by antibody to the glomerular endothe-
hal cell [461, the principal predicter of injury appears to be the
insertion of C5b-9 into cell membranes [26]. However, although
C5b-9 mediates injury in both the ATS model of experimental
mesangial proliferative glomerulonephritis [47], and the PHN
model of membranous nephropathy [18, 48], the proliferative
responses by the mesangial cell and GEC are different. We have
reported that the onset of mesangial cell proliferation in ATS
model of glomerulonephritis was associated with a striking de-
crease in p27 levels, which were barely detectable when maximal
mesangial cell proliferation occurred [171. Furthermore, the res-
olution of mesangial cell proliferation in this model coincided
with the normalization of p27 [17]. In contrast, the current study
shows that C5b-9 mediated injury in PHN is associated with an
early and sustained increase in p21 and p27 levels. Thus, in the
ATS and PHN models where cell injury is immune (C5b-9)
mediated, the cyclin kinase inhibitors are differentially expressed
by the respective cell targets and may determine the nature of the
proliferative response in vivo.
bFGF decreases the expression of p21 in rats with PHN
Floege et al [12] and Kriz et al [11] have previously shown that
giving the cytokine bFGF to rats with P1-IN markedly augments
GEC injury. This is characterized by increased matrix formation,
and an increase in the number of GEC mitotic figures and GEC
ploidy. However, the number of GEC were unchanged. These
findings lead us to ask if the increase in GEC mitosis and ploidy
following bFGF infusion was due to an alteration in the expres-
sion of the cyclin kinase inhibitors. Our third major finding was
that there was a differential expression in p21 and p27 following
the infusion of bFGF to rats with PHN. We showed that the levels
of p21, but not p27, were markedly decreased by bFGF. Interest-
ingly, the expression of CDK2 was unchanged. Taken together,
* these results further support the notion that the cyclin kinase
inhibitors, in particular p21, may be major regulators of GEC
proliferation in vivo.
Our study focused on cell cycle regulatory proteins that are
involved in the GuS phase of the cell cycle (where DNA synthesis
occurs) and not the G2/M phase (where cell division occurs).
Therefore, the current study provides evidence that may explain
why GEC DNA synthesis is limited compared to other types of
glomerular disease, such as the ATS model of experimental
mesangial cell proliferation, but does not explain why GEC
cannot undergo mitosis. The latter requires the G2/M phase cell
cycle proteins, cyclin B and cdc2. However, at this time the cyclin
kinase inhibitors of G2/M are not as well characterized as those of
GuS. Future studies are needed to examine the role of G2/M
cyclin kinase inhibitors in preventing GEC mitosis.
GEC undergo apoptosis in vivo following severe injury
The fourth major finding in the current study was that GEC
undergo apoptosis following severe injury. Similar to previous
studies [12], we were unable to document an increase in apoptosis
in PHN in vivo in the current study. However, when injury to GEC
is augmented with bFGF, we now show, using a more sensitive
method (TUNEL), an increase in DNA laddering, which may
represent apoptosis. This differs from what was previously de-
scribed where apoptosis was not detected (using different meth-
ods) following bFGF infusion in PHN rats [12]. Therefore, further
studies are needed to examine if the increase in TUNEL shown in
the current study does represent apoptosis. The mechanisms
responsible for the increased TUNEL staining were not directly
addressed in the current study. One possibility is that GEC ploidy
that occurs in human and experimental disease of the GEC, and
is increased by bFGF, causes DNA "damage." We propose that
GEC apoptosis may prevent the propogation of damaged DNA to
daughter cells. Many cells only undergo apoptosis once they
engage in the cell cycle. Thus, another possible mechanism why
GEC undergo apoptosis following the administration of bFGF to
PHN rats is that more cells are now engaged in the cell-cycle, and
thereby can enter the apoptotic pathway. The consequences of
GEC apoptosis are not known. However, the observation that
DNA synthesis is increased in this model and the GEC number
remain unchanged, raises the possibility that apoptosis may limit
the increase in cell number.
In summary, in the current study we showed that the low
proliferative capacity of the GEC in vivo following injury in the
PHN model of membranous nephropathy was associated with an
up-regulation in the cyclin kinase inhibitors p21 and p27. Reduc-
ing the levels of p21 in PHN with bFGF resulted in an increase in
GEC mitosis and ploidy, and with an increase in GEC apoptosis.
This study therefore provides compelling evidence that the limited
proliferation by the GEC may be due to an increase in the cyclin
kinase inhibitors p21 and p27.
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APPENDIX
Abbreviations are: p21: p21CIPIIWAF1/CAP1/SDI1
p27: p27 KIPI
CM: cyclin kinase inhibitor
CDK: cyclin dependent kinase
GEC: glomerular epithelial cell
PHN: passive Heymann nephritis
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